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ABSTRACT
Information on acute and chronic systemic toxicity, arising from the oral, dermal and inhalation routes 
of exposure, are key elements in the regulatory assessment of chemicals. Traditionally, this 
information is obtained from animal studies. However, due to animal welfare and cost considerations, 
alternatives to animal experiments are being sought, and regulatory frameworks are providing an 
increasing opportunity or obligation to use such methods. This report provides a review of different 
computational estimation methods for predicting acute and chronic systemic toxicity. It provides an 
overview of Quantitative Structure-Activity Relationship (QSAR) models published in the literature, 
commonly used software tools, and available databases suitable for QSAR analysis. It also briefly 
explains the Threshold of Toxicological Concern (TTC) concept and how this is used in prioritising 
chemicals for further assessment and preliminary risk characterisation.
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11. Introduction
Systemic toxicity studies aim at investigating the effects of chemicals in laboratory animals exposed to 
various dosage regiments for different durations. Exposure is generally through the oral, dermal or 
inhalation routes. The information from systems toxicity studies is used in hazard and risk assessment 
of chemicals occurring in food, industrial chemicals, biocides, and cosmetics. In this report, we give an 
overview of the (Q)SAR models and software packages used in the assessment of acute systemic 
toxicity, chronic systemic toxicity and organ- and system-specific toxicity, as well as the databases 
available for obtaining such data.
2. Acute systemic toxicity
Acute toxicity describes the adverse effects caused by either a single exposure to a chemical substance
or multiple exposures within 24 hours.. The acute lethal dose to 50% of the treated animals (LD50
value) is the basis for the hazard assessment and classification of chemicals and is widely used for 
regulatory purposes. However, the LD50 value presents some drawbacks when used for QSAR 
modelling. First, acute toxicity effects may result from a wide spectrum of biokinetic, cellular and 
molecular events. Converting the complex, whole-body phenomena related to acute toxicity into a 
simple number necessarily leads to a loss of information. Second, available data are highly variable, 
having been generated by different laboratories, protocols, animal species and strains. This undermines 
the reliability and repeatability of acute toxicity measurements. These facts complicate the modelling 
process and may explain why there are relatively few (Q)SAR models and expert systems for 
predicting oral acute toxicity, in comparison with other endpoints.
2.1 Literature models
Several reviews have been published on available models for rodent (rat and mouse) systemic toxicity 
(Cronin et al., 2003; Tsakovska et al., 2008; Devillers & Devillers, 2009). In comparison with other in 
vivo endpoints for which extensive datasets with diverse compounds have been used to construct 
QSARs, most literature-based QSAR models of rodent oral acute toxicity are specific to one or a small 
number of classes of chemicals. The examined classes and a summary of model characteristics for 
these local models are given in Table 1. Usually, hydrophobicity and the electronic and steric effects 
have been identified as parameters of high importance for the modelled toxicity. These models are 
generally accompanied by a statement of applicability domain, which is defined on the basis on 
inclusion/exclusion rules regarding the chemical class(es) comprised in the training set.
Among the local QSAR model for rodent oral acute toxicity, organophosphates have received 
particular attention. For example, Devillers (Devillers, 2004) used partial least squares (PLS) 
regression and artificial neural network (ANN) analysis to predict rat LD50 values for 51 
organophosphorus pesticides. This study highlighted the usefulness of descriptors such as lipophilicity, 
molar refractivity, H-bonding acceptor ability (HBA) and H-bonding donor ability (HBD). On the 
other hand, Garcia-Domenech and coworkers (García-Domenech et al., 2007) have proposed a model 
using solely topological indices to predict rat acute toxicity of 62 organophosphorous pesticides by 
multiple regression analysis. Neither of these models is available in a form suitable for practical use, 
but they do identify useful descriptors for further research and QSAR development.
A number of QSAR models for predicting in vitro cytotoxicity data are available (e.g. Chan et al.,
2007); and these have been reviewed by Tsakovska et al. (2008). While such models are not directly 
relevant to the regulatory assessment of acute toxicity, they may provide insights into the mechanisms 
of cytotoxic action, and may provide useful supporting information, for example when performing a 
2read-across of LD50 values between analogues. As with other models, they would need to be 
implemented in the form of a user-friendly tool.
In vitro endpoints, and in particular cytotoxicities, have also been used as descriptors in combination 
with structural parameters. This approach is called quantitative structure-activity-activity analysis 
(QSAAR). An example of this approach, reported by Lessigiarska et al. (2006), used rat hepatocyte 
toxicity data for QSAAR modelling of an heterogeneous set of 48 compounds, comprising pesticides
(malathion, warfarin, lindane, chloroform), simple organics, alkaloids and drugs. Interestingly, for this 
particular dataset, models for rat and mouse acute toxicity showed a better fit when based solely on 
structural descriptors (i.e. hydrophobicity factor, the electrotopological state descriptor and the number 
of six-member rings), than when in vitro endpoints were included. QSAAR modelling could be a 
promising approach for acute toxicity prediction, particularly in cases when a significant correlation 
exists between in vivo data (LD50) and in vitro cytotoxicity (IC50), and the additional inclusion of 
physicochemical parameters serves to improve the correlation. It has been observed that direct in vitro-
in vivo correlations are generally poor, even within the same species, especially for large chemical 
datasets (ICCVAM et al., 2001). In these in vitro studies, most of the compounds showing a bad linear 
fit are underpredicted on the basis of the in vitro data. In practical terms, QSAAR could be particularly
useful if high-throughput screening methods are used to generate the in vitro data. 
Zhu et al. (Zhu et al. 2009a) have recently reported a novel modelling approach for predicting rodent 
acute toxicity. In this study, the authors divided the dataset (ZEBET) into two groups, i.e. compounds 
with a good or a bad IC50/LD50 correlation. Then by using exclusively chemical descriptors 
(DRAGON) and the k-nearest neighbour method, the authors developed specific QSAR models as 
follows: a) binary classification models to partition external compounds into two groups, i.e. i) 
compounds having a good IC50/LD50 linear correlation within a defined band, and ii) those falling 
outside the band, and b) class-specific models to predict LD50 values for each subclass. The LD50
prediction accuracy of the resulting models proved superior to TOPKAT models applied to the same 
external test set of rodent acute toxicity data (RTECS chemicals). The innovative aspect of this 
hierarchical two-step modelling approach is that it used the relationship between in vitro and in vivo
acute toxicity data as the initial information for the construction of QSARs for predicting LD50 values 
which are based solely on chemical descriptors. Although no mechanistic rationalisation of the 
modelling approach was provided by the authors, it could be useful to discriminate between chemicals 
belonging to class i) vs. class ii), as described above, which may reflect biotransformation or other in 
vivo effects which cannot be represented by in vitro toxicity data alone. Nevertheless, a disadvantage 
of this modelling approach is that it requires highly specialised expertise and tools, which may not be 
transferable to other users and computational platforms. Due to its complexity, it is difficult to judge 
whether the models are reproducible, as neither the algorithm used is transparent, nor the exact 
compositions of the training and test sets are available. 
In addition to the above-mentioned local models, a number of QSAR models for rat oral acute toxicity 
have been developed using large datasets (global models) have been recently reported by Zhu and 
coworkers (Zhu et al., 2009b). These models were built by using a combinatorial QSAR modelling 
approach, including several sets of descriptors and employing several statistical modelling methods 
(e.g. nearest neighbour methods, the Random Forest predictor, and the FDA MDL QSAR method). 
Ultimately, consensus models were developed by averaging the predicted LD50 for every compound 
using all five models, which afforded higher prediction accuracy as compared to individual models. 
However, as a result of using a large number of descriptors, which are often sparsely populated, the 
multidimensional space defined by each of these models is complex and fragmented. As a result of the
high complexity of the modelling procedure, these models are difficult to reproduce, even by a 
specialist, and thus they are not easily transferable and practically useful. The consensus modelling
developed in this study is nevertheless interesting as the basis for further research in computational 
methods to predict acute oral toxicity.
3A recent study by Raevsky and coworkers (Raevsky et al., 2010) proposed the so-called Arithmetic 
Mean Toxicity (AMT) modelling approach, which produces local models based on a k-nearest 
neighbours approach. The authors showed that LD50 values could be predicted with r2 values up to 
0.78, depending on the selection of nearest neighbours (analogues), which is significantly better than 
the statistics associated with in vitro-in vivo correlation (typically r2 values less than 0.5). The error of 
prediction was in the range 0.30 to 0.52 log units, which is comparable with the experimental error 
associated LD50 determination. These predictions are based on the following general formula, in which 
LD50 AMT refers to the average  LD50 values of one or more pairs of analogues (nearest neighbours), 
and the coefficients depend on the specific settings (how many pairs of analogues are included in the 
calculation):
log (1/LD50)exp= a0 + a1* log (1/LD50) AMT                                               
This approach is transparent and reproducible, but would need to be implemented in a software tool for 
ease of application. It can be thought of as an automated read-across approach.
2.2 Software
Software tools capable of predicting endpoints related to systemic toxicity are listed in Table 2.
The commercial software ACD/Tox Suite (now developed and marketed by Advanced Chemistry 
Development [ACD/Labs] and formerly by Pharma Algorithms as ToxBoxes) predicts toxicity in both 
the mouse and rat for various administration routes, including oral, as either quantitative LD50 values 
or classification into the five GHS categories.
The statistically-based programs TOPKAT and MCASE use multiple QSARs on small and
homogenous sets of data. The rat oral LD50 module in TOPKAT comprises 19 regression analyses 
developed using experimental values of approx. 4000 chemicals from RTECS, including pesticides 
and industrial chemicals. The rat oral LD50 module in MCASE (named A56) is based on and 
comprises data for 7920 chemicals from the FDA, WHO and NTP datasets. Tunkel and coworkers 
(Tunkel et al., 2005) compared the performance of the TOPKAT and MCASE rat LD50 modules 
against an external test set of 73 organic compounds covering 32 chemical categories retrieved from 
submissions to the EPA High Production Volume (HPV) Challenge Program 
(http://www.epa.gov/chemrtk/). The predictive accuracy of each software tool was assessed by 
applying the EPA’s New Chemical classification approach 
(http://www.epa.gov/oppt/newchems/index.htm), from the low-concern class (>2000 mg/kg) to the 
high-concern class (<15 mg/kg). While neither model was able to classify all 73 compounds, TOPKAT 
correctly classified 67% of the chemicals, while MCASE classified 70% correctly. However, it should 
be noted that the test set used was significantly skewed toward “low concern” chemicals, which both 
models predicted correctly with a high degree of accuracy (82% and 100% correct for TOPKAT and 
MCASE, respectively). Moreover, a high degree of false negatives was found for moderate and high 
concern HPV chemicals (TOPKAT, 72%; MCASE, 100%), suggesting that these programs are less 
reliable for the identification of more toxic compounds. The authors also compared the model outputs 
against  the GHS five-tier scheme for classification of rat oral acute toxicants (<5, 5-50, 50-300, 300-
2000, and 2000-5000 mg/kg), which is similar to the one adopted by EPA (<15, 15-50, 50-500, 500-
2000, >2000 mg/kg). When compared against the GHS scheme, the ability of TOPKAT and MCASE 
to produce correct classifications was 73% and 70%, respectively, for the HPV test set chemicals, 
thereby changing slightly with respect to the EPA scheme, albeit enough to invert the rank order of 
these models. Overall, these results support the usefulness of the TOPKAT and MCASE tools when 
used for hazard classification.
Other software tools available for predicting acute toxicity (LD50) to rat/mouse, are also available, such 
as MDL QSAR and TerraQSAR. The TerraQSAR software models, based on neural networks, include 
modules for predicting both oral and intravenous LD50 values in mice and rats (http://www.terrabase-
inc.com/).
42.3 Databases
Sources of rat LD50 values which may be suitable for the development of QSARs, the application of 
read-across, and the evaluation of high-throughput in vitro methods, are listed in Table 3. In particular, 
Acutoxbase (Kinsner-Ovaskainen et al., 2009) is being database developed in the context of the EU 
FP6 project ‘A-Cute-Tox’ (www.acutetox.org), which aims to optimise and “pre-validate” an in vitro
testing strategy for predicting acute human toxicity. At present, Acutoxbase is accessible only to the 
partners of the A-Cute-Tox project, but it is foreseen that (part of) the database will be placed in the 
public domain after the project is completed (July 2010). It is not yet decided when, and to what 
extent, the A-Cute-Tox data will be made available by publication of this database. However, parts of 
the data have been published in the literature (Kinsner-Ovaskainen et al., 2009).
In order to be useful for QSAR development, datasets should be first curated, i.e. the accuracy of the 
structures should be verified and the quality of biological data should be reviewed. In addition, 
inorganic and organometallic compounds, salts, and compound mixtures are often removed from the 
analysis. For the development of QSARs, LD50 values should be converted to log[1/(mol/kg)] (if 
originally expressed as mol/kg). Finally, approximate LD50 values should be converted to discrete 
values, and multiple LD50 values from different labs/experiments should be converted to a single 
value. The ChemIDplus and ZEBET databases have been recently employed as data sources for QSAR 
analyses (Zhu et al., 2009a,b).
2.4 Conclusions
On the basis of the literature review, it is concluded that some currently available software tools (e.g. 
TOPKAT and MCASE) are useful for predicting acute toxicity in categorical terms (e.g. in terms of 
GHS classifications). However, these tools should be further investigated in relation to apparently high 
degree of false negatives generated, since this would be undesirable in the regulatory assessment of 
pesticides. The performance of other software tools in predicting acute toxicity should also be 
investigated. It is recommended that targeted studies are carried out to explore the usefulness of these 
software tools not only for classifying chemicals but also for making quantitative predictions of LD50
values for chemical inventories of regulatory importance (e.g. pesticides). 
In the scientific literature, QSAR models have been generated for sets of congeneric compounds 
(organophosphates, aromatic amines, anilines, etc.) and are scattered over many original publications 
(see Table 1). Despite their limited applicability when taken individually, these local models might be 
usefully combined into an expert system for toxicity predictions. Further research and development in 
this area is therefore encouraged. In addition, several recent research studies (Zhu et al, 2009; Raevsky 
et al., 2009) have demonstrated the ability to make reasonable quantitative predictions for structurally 
diverse datasets, especially when high throughput bioactivity data are used in combination with 
traditional QSAR descriptors. These approaches should be explored further with a view to practical 
implementation. In this respect, the future availability of the models developed by Zhu et al. for use as 
LD50 predictors via the EPA website and the ChemBench web portal (Zhu et al., 2009a) are promising 
initiatives.
53. Chronic systemic toxicity
Chronic (repeated dose) toxicity refers to the general toxicological effects in mammals occurring as a 
result of prolonged and repeated (oral, dermal or inhalation) exposure to a substance. The general 
toxicity includes a wide range of possible adverse effects including changes in morphology, 
physiology, growth, development or life span which result in impaired functional capacity, impaired 
capacity to compensate for additional stress or increased susceptibility to the harmful effects of other 
environmental influences.
The most commonly performed animal tests are the subacute (28-day) and subchronic (90-day) oral 
toxicity tests in rodents. Testing is sometimes performed with a longer testing period (12 months or 
more), and sometimes with in a non-rodent species (e.g. dogs, primates). The studies are used to 
identify adverse effects on various organs and tissues (e.g. liver, kidney, central nervous system, 
reproductive organs, immune system, and the endocrine system), and to establish a dose metric for risk 
assessment - the lowest dose that induces an adverse effect (Lowest Observed Adverse Effect Level; 
LOAEL) or the highest dose with no biologically or statistically significant adverse effects (No 
Observed Effect Level; NOEL). In this assessment, all toxicological responses are taken into account 
and the critical (most sensitive) effect is identified. The results of repeated-dose testing can also be 
used to classify chemicals on the basis of systemic toxicity. Within the Globally Harmonised 
Classification System (GHS) for chemicals, the results of repeated dose studies can be used, in a 
weight-of-evidence approach, to place systemic toxicants in two hazard categories.
Thus, chronic toxicity is not really a single endpoint, but a common term for a multitude of biological 
effects that have different mechanisms, occur in different tissues and organs and over different time 
scales. This presents a challenge for QSAR modelling, which should ideally focus on groups of 
chemicals with a common mode of action. Perhaps for this reason, there have been few attempts to 
develop QSAR models for chronic toxicity in mammalian.  Some of these studies have been reviewed 
in Tsakovska et al. (2008).
3.1 Literature models
A summary of literature-based QSARs for repeated dose toxicity are given in Table 4.
Garcia-Domenech and colleagues (de Julian-Ortiz et al., 2005; Garcia-Domenech et al., 2006) used the 
same data used in the TOPKAT training set (EPA and NTP reports) to develop multilinear regression 
models for predicting the chronic LOAEL and linear discriminant analysis models for classifying 
chemicals into two or three groups based on LOAEL ranges. They showed that models based on the 
EPA pesticides database were better than models based on the NTP database. The models are 
transparent and have the advantage of being based on molecular connectivity indices, which are easily 
computed, invariant molecular descriptors. The error of the regression models was equivalent to the 
variance in the underlying experimental data. These models could be useful if implemented in the form 
of software that also generates the necessary descriptors,
Mazzatorta et al. (2008) reported a regression-based QSAR for rat chronic toxicity (180 or more days). 
The model was developed by applying multivariate analysis to LOAELs for 445 diverse compounds 
selected from multiple sources, including the dataset of Munro et al. (1996) and various chemical 
assessment reports (JECFA, JMPR, NCI and NIH). The training set, which was not provided in the 
paper, included pesticides, drugs and natural products. The resulting model, based on 19 easily 
computed DRAGON descriptors, is explicitly defined. Since the prediction error of 0.70 was found to 
be close to the experimental error of 0.64 log units, the model was considered to have reasonable 
predictive ability. The model was analysed in terms of the mechanistic significance of the descriptors, 
and it was argued that the chronic toxicity is driven by the bioavailability of the compounds, which 
constitutes a baseline effect, plus excess toxicity possible described by a few chemical moieties. 
6A model for predicting oral MRTD values and NOELs in humans was developed by Matthews et al.
(2004a), who used MRTD data for 1309 pharmaceuticals and defined NOEL as MRTD/10. MultiCase 
was used to develop a classification model to distinguish between high-toxicity chemicals (having low 
MRTDs) and low-toxicity chemicals (having high MRTDs) on the basis of structural alerts. While 
most of the training set is made available (Matthews et al. (2004b), the algorithm is not provided, so it 
would be necessary to have a MultiCase license in order to reproduce and use the model. The model is 
reported to have a high positive predictivity (93%) at the same time as a low false positive rate (5%), 
which implies the model can be used to reliably identify toxic chemicals. Examples are given of five 
structural alerts for high toxicity, out of a total of 134 derived by the MultiCase algorithm. Thus, little 
of knowledge obtained is transferable to another platform. Interestingly, an additional analysis showed 
a poor correlation (R2 of 0.2) between the MTD in rodents and the MRTD in humans, on the basis a 
dataset of 326 pharmaceuticals for which the human and rodent data were available. The implications 
of this finding were not discussed. Overall, this study presents an interesting approach to the 
estimation of chronic toxicity in humans, but due to a lack of transparency in the algorithm, it would 
be necessary to purchase a MultiCase license in order to apply the model. A cheaper and more 
transparent alternative would be to use alternative modelling approaches to explore the dataset and 
relate the experimental results to rodent data. 
The first reanalysis of the FDA MRTD database to be published was performed by Maunz & Helma 
(2008). They applied Support Vector Regression (SVR), a pattern recognition technique, to predict 
MRTD on the basis of local clusters of similar molecules. This is an example of an instance-based 
model (or lazy learning) since a local model for each query compound is built from structurally similar 
compounds in a dataset. It can be thought of an automated read-across. On the basis of the paper alone, 
this modelling approach is not transferable and the applicability domain is not defined in an easily 
interpretable manner. However, the authors have promised to implement the approach in the freely 
available Lazar software (see above), which could make it useful to the non-specialist.
An example of the application of “manual” read-across to predict the 28-day NOAELs of substituted 
anilines has been illustrated by Sakuratani et al. (2008). This can be performed without any 
computational tools but is facilitated by using a tool such as the OECD QSAR Toolbox. This process 
requires a fair degree of computational and toxicological expertise. 
3.2 Software
Software tools capable of predicting repeated dose toxicity are given in Table 2. At present, the best 
known is probably TOPKAT, which predicts oral rat chronic LOAEL values. The model includes five 
regression-based models for five classes of chemicals (acyclics, alicyclics, heteroaromatics, single 
benzenes and multiple benzenes), developed on the basis of 393 chemicals from various sources (EPA 
and National Cancer Institute/National Toxicology Program (NCI/NTP) databases; FDA drug 
applications reports; and the open literature). The paper describing the original model development 
(Mumtaz et al., 1995), based on 234 structurally-diverse chemicals for which chronic data (12 months 
or more) were available from the above-mentioned sources, provides a transparent description of the 
model – it is mulitilinear regression QSAR based on 44 structural descriptors. In contrast, the 
algorithm for the updated TOPKAT model, based on five regression models and an extended dataset of 
393 chemicals, has not been published.
In a model assessment study by Venkatapathy et al. (2004), the predictive performance of TOPKAT 
was tested against 343 chemicals from the EPA’s Office of Pesticide Programs (OPP) database. After 
removal of compounds that TOPKAT could not recognise or which generated various types of
warnings, the percentages of chemicals in TOPKAT’s database that had a LOAEL predicted within a 
factor of 2, 5 and 10 of the experimental LOAEL were 65%, 83%, and 91%, respectively. When 
testing against chemicals not already in TOPKAT’s database (i.e. an external validation), the 
corresponding percentages were 34%, 57% and 72%. Similar statistics were obtained when the 
TOPKAT predictions were compared against 313 chemical in the “IHP database”, so-called because it 
7was derived the Integrated Risk Information System (IRIS), Health Effects Assessment Summary 
Tables (HEAST), and Provisional Toxicity Value (PTV) databases. If prediction within a factor of 2 is 
taken as the criterion for “correct classification”, this implies a misclassification rate of 35-66%; and if 
a factor of 10 is adopted, the corresponding misclassification rate would be 9-28%.
In another assessment, Tilaoui et al. (2007) investigated the ability of TOPKAT to predict the 
LOAELs of substances typically occurring in food, on the basis of 607 substances taken from Munro 
et al. (1996). After excluding the 267 substances in the TOPKAT training set, the number of validation 
substances was reduced to 340. Of those 340 molecules, 287 had predicted LOAELs with the model 
applicability domain (OPS), of which 86% were predicted within a factor of 2.
In addition to providing point estimates of chronic toxicity, the similarity search capacity of TOPKAT 
can be used to identify analogues in the TOPKAT database for use in read-across assessments. For 
example, in order to predict the LOAEL of dichlorobenzophenone (DCBP), which is a metabolite of 
chlorobenzilate, dichlorodiphenyltrichloroethane, and dicofol, Mougdal et al. (2003) identified 47 
potential analogues in the TOPKAT database, of which five were selected on the basis that there were 
toxicity data in an EPA database (IRIS, HEAST or PTV). Among the five potential surrogates, 
chlorobenzilate was chosen as a surrogate for DCBP, since it had the most conservative chronic oral 
reference dose (RfD). The RfD is the US EPA’s maximum acceptable oral dose of a toxic substance, 
obtained by dividing the NOEL or LOAEL by various uncertainty factors.
The other main software tool capable of predicting LOAELs, is a module of the recently developed 
MolCode Toolbox. A QMRF for this model is available in the JRC QSAR Model Database.
3.3 Databases
There are two main databases suitable for the development and assessment of (Q)SARs for repeat-dose 
toxicity (Table 5). The RepDose database developed by the Fraunhofer Institute (Bitsch et al., 2006) 
contains NOELs and LOAELs for over 650 industrial chemicals, but is not made publicly available. A 
database of human Maximum Recommended Therapeutic Dose (MRTD) values has been compiled 
and made publicly available by the US FDA (Matthews et al., 2004b). 
In addition to these databases, there are several datasets in the published literature. Munro et al. (1996) 
developed a database of 612 structurally well-defined organic chemicals, divided into the three 
structural Cramer classes (Cramer et al., 1978) and associated with 2944 (subchronic and chronic) 
NOELs derived from non-carcinogenic endpoints in oral rodent or rabbit studies. This database has 
provided the basis of the TTC concept. Oral NOELs for 45 consumer product ingredients (not in the 
Munro database) have been published by Blackburn et al. (2005). 
3.4 Conclusions
The availability of (Q)SAR models for chronic toxicity endpoints is currently very limited. Since a 
large number of potential targets and mechanisms are associated with repeated dose effects, it is 
unlikely that any single model or software tool will be capable of making reliable predictions for all 
chemicals of interest to dietary risk assessment. The most commonly used software tool at present is 
TOPKAT, and despite the lack of transparency in its predictions, several studies have shown that it 
gives reasonable predictions for a range of chemicals (including pesticides, industrial chemicals). 
Another more recently developed tool is a module of MolCode Toolboxes. Predictions from such tools
could be used in a weight-of-evidence approach along with additional data. Additional research 
investigations into the applicability of TOPKAT and MolCode Toolboxes across a wide range of food 
chemicals would be worthwhile. In addition, a transparent expert system or battery of (Q)SAR models 
needs to be developed for this endpoint. The studies performed by Garcia-Domenech and co-workers, 
using the same data as used for TOPKAT, have shown that simple, transparent regression and 
classification models can be developed, with an equivalent performance to TOPKAT. Thus, it is 
8recommended that the predictive abilities of these models are compared, and refinements of the 
literature models explored.
A useful alternative to QSAR when limited data are available is to estimate the toxicity of a chemical 
of interest by reading across from the corresponding data for suitable analogues. Thus, read across 
provides an alternative or additional approach to the use QSAR in the estimation of chronic toxicity. 
Several studies have demonstrated the usefulness of reading across chronic toxicity data, and at least 
one freely available software tool is available to automate the task in the case of human MRTDs 
(Lazar). In view of the limited availability of QSARs and predictive software for chronic toxicity 
effects, the read-across approach merits further investigation, and automated software should be 
developed further.
4. Organ-specific and system-specific toxicity
In addition to models for acute and repeated dose toxicity at the in vivo level, a number of models have 
been developed for predicting toxicities at the cellular, tissue and organ levels. Some of these models 
are based on the concept of reactivity-based toxicity. The covalent binding of reactive electrophiles to 
cellular targets (i.e., nucleophilic sites of macromolecules) has the potential to initiate a chain of 
biological effects resulting in adverse events in specific organ and system toxicities. Electrophilic 
chemicals could, for example, deplete glutathione (GSH) and protein thiols. A number of (Q)SAR 
studies have focused on modelling toxicity to some of these systems, sometimes by modelling in vitro
data.
4.1 Hepatic and urinary tract toxicities
Matthews and co-workers (Matthews et al. 2009b) have recently conducted an evaluation study to 
compare the performances of in-house models built using four QSAR software tools, CASE/MC4PC, 
MDL-QSAR, BioEpisteme, and Leadscope Predictive Data Miner), in predicting serious hepatobiliary 
and urinary tract toxicities of drugs  Models were constructed for five types of liver injury (liver 
enzyme disorders, cytotoxic injury, cholestasis and jaundice, bile duct disorders, gall bladder 
disorders) and 6 types of urinary tract injury (acute renal disorders, nephropathies, bladder disorders, 
kidney function tests, blood in urine, urolithiases). The training set comprised approximately 1600 
pharmaceuticals based on observations made in humans in pharmaceutical clinical trials and/or post-
market surveillance by the FDA (Ursem et al. 2009). For model construction, the toxicities of the 
training set drugs (continuous values) were classified either as being of low risk (0, negative) or as 
high risk (1, positive) by identification of an optimised breakpoint activity value (BP) distinguishing 
active from inactive drugs. The best QSAR models exhibited an overall average 92% coverage, 87% 
specificity and 39% sensitivity. Furthermore, the sensitivity could be increased to 56% by combining 
any two of these programs, or 68% by calling a chemical positive if predicted to be positive in at least 
one of four programs. It was thus argued that, collectively, the four methods offer a high confidence 
method for predicting serious drug hepatobiliary and urinary tract toxicity. This provides evidence that 
a consensus prediction strategy provides a means of optimising predictive ability. However, while the 
models reported in this study are applicable to drugs, it is not clear to what extent they are applicable 
to other types of chemicals. Furthermore, the models are not transferable – it would be necessary to 
purchase the four software tools and rebuild the models from the same dataset.
A number of studies have developed local QSAR models for hepatocyte toxicity. For example, Chan 
and coworkers have used linear regression analysis to develop several correlations between 
physicochemical parameters and hepatocyte toxicity of a few chemical classes: alpha,beta-unsaturated 
esters, : alpha,beta-unsaturated aldehydes, p-benzoquinones and halobenzenes (Chan et al., 2007, 
2008a,b,c). Such models are not directly useful in the regulatory assessment of chemicals, but they 
have helped to establish mechanisms of hepatotoxicity, and they have identified useful descriptors for 
9further model development. For example, a QSAR for hepatocyte toxicity of alpha,beta-unsaturated 
esters, consisting of acrylates and methacrylates, indicates that toxicity is correlated with electronic 
parameters (ELUMO and partial charges of the carbon atoms in the reactive centre) as expected for a 
mechanism based  on electrophilic reactivity. 
In a more recent study, building upon previous work by (Moridani et al., 2003), Roy and Popelier 
describe the advantages of quantum-chemical descriptors (quantum topological molecular similarity 
indices) over physicochemical electronic descriptors (pKa and Hammett electronic constant) for 
predicting the hepatocyte toxicity of phenols (Roy et al., 2008). Phenols are widely distributed in 
edible plants, and are used by the chemical industry as chemical intermediates or biocides. While it is 
well known that polyphenols can protect cells from the oxidative stress, there is also an increasing 
evidence of their prooxidant cytotoxicity (Nemeikaite-Ceniene et al., 2005). Because of the large 
human and environmental exposure to phenols, there is much interest in assessing their potential 
hazard. 
4.2 Local models of nephrotoxicity 
Very few (Q)SAR studies of nephrotoxicity have been published, and those identified focus on very 
small groups of compounds, which limits the applicability of the resulting models. For example, 
structural alerts have been derived for the rat nephrotoxicity of 1,2- and 1,4-naphthoquinones (Munday 
et al., 2007), and a QSAR has been developed for the nephrotoxicity of haloalkenes (Jolivette et al.,
2002). Haloalkenes are high-volume chemicals used in industrial, synthetic, and pharmaceutical 
applications and are common environmental pollutants. Many haloalkenes are known to be 
nephrotoxic in rodents after bioactivation via the cysteine conjugate •-lyase pathway, which is 
triggered by formation of hepatic glutathione S-conjugates, a reaction catalysed by cytosolic and 
microsomal glutathione transferases (Anders et al., 1998). The study by Jolivette and Anders (Jolivette 
et al., 2002) related the nephrotoxicity of nine haloalkenes to their lowest unoccupied molecular orbital 
energies, ELUMO, reflecting their propensity for conjugation reactions catalysed by glutathione 
transferase enzymes.
4.3 Neurotoxicity 
Neurotoxicity is an adverse effect on the functioning of the nervous system resulting from exposure to 
a chemical substance. The standard oral 28-day and 90-day toxicity studies include endpoints capable 
of detecting neurotoxic effects (e.g. clinical observations, behavioural changes, motor activity 
assessment, neurochemical changes and histopathological changes in the central or peripheral nervous 
system). 
Only a few (Q)SAR studies have focused on the effects of chemicals on the central nervous system, in 
some cases through the modelling of in vivo toxicity (Table 6). For example, Crofton (1996) described 
a SAR study of 14 different triazole fungicides which cause hyperactivity in rats. A QSAR for PCB 
neurotoxicity (Pessah et al., 2005), based on data for 28 ortho-substituted PCBs, and building on 
earlier work (Nevalainen et al., 1994), revealed a relationship between electronic descriptors 
(ELUMO, EHOMO, the ELUMO•EHOMO gap, and molecular polarisability) and the binding affinity 
of PCBs to the aryl hydrocarbon (Ah) receptor. In particular, impairment of the developing nervous 
system by PCBs has been linked to their ability to alter the spatial and temporal fidelity of Ca2+ 
signalling in muscle and nerve cells through one or more receptor-mediated processes (Pessah et al., 
2009).
Among the commonly used software tools, Derek for Windows v.12 estimates neurotoxicity using the 
following structural alerts: •-diketone or precursor, acrylamide or glycidamide, nitroimidazole, carbon 
disulphide or precursor, pyrethroid, 1-methyl-1,2,3,6-tetrahydropyridine, lead or lead compound and 
organophosphorus ester.
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4.4 Immunotoxicity
Immunotoxicity is an adverse effect on the functioning of the immune system resulting from exposure 
to a chemical substance. The standard oral 28-day and 90-day toxicity studies include endpoints 
capable of detecting immunotoxic effects (e.g. haematological parameters, alterations in immune 
system organ weights such as spleen and thymus, and histopathological changes in immune organs 
such as spleen, thymus, lymph nodes and bone marrow). 
Immunotoxicity can refer to immunosuppression in humans (caused, for example, by benzene and 
halogenated aromatic hydrocarbons), autoimmune disease (for example the pesticide dieldrin induces 
an autoimmune response against red blood cells, resulting in haemolytic anaemia), and allergenicity 
(chemicals which stimulate the immune system can cause allergies or hypersensitivity reactions such 
as anaphylactic shock). Thus, immunotoxicity refers to a wide variety of biological effects, many of 
which involve complex biochemical networks. 
No (Q)SARs for predicting immunotoxicity specifically were identified in the literature review, which 
is perhaps not surprising given the biological complexity of immunotoxic effects.
4.5 Conclusions
In general, the modelling of organ-specific and system-specific effects represents an underdeveloped 
field, ripe for future research but far from regulatory applications. Future research initiative could 
include, for example, re-examination of the datasets for hepatobiliary and urinary tract toxicities of 
drugs with a view to developing more accessible models and assessing their applicability to chemicals 
other than pharmaceuticals. In addition, the concept of reactivity-based toxicity, now established as a 
plausible mechanism for hepatocyte toxicity, could be further exploited using data from hepatocyte 
cultures and cell lines. In some areas, such as immunotoxicity, short-term progress seems unlikely. The 
complexity of such effects probably means that alternative (e.g. systems biology) approaches will need 
to be investigated in the longer term. Ultimately, it seems unlikely that QSAR models for organ-
specific and system-specific effects will be used directly for regulatory purposes, where the focus is on 
the assessment of apical endpoints. However, these models could become a useful contribution to 
priority setting exercises, and provide means of providing supporting information, such as on the 
mechanisms of toxicity.
5. The Threshold of Toxicological Concern (TTC) approach
Chronic systemic toxicity studies after oral exposure have been used to develop the Threshold of 
Toxicological Concern (TTC) concept. The TTC is a generic human exposure level for chemicals 
below which there is low probability of risk to human health, assuming lifetime exposure. The 
principle of TTC is built on the premise that a safe level of exposure can be identified for chemicals 
present at low concentrations in the diet, even for those with unknown toxicity, on the basis of their 
chemical structure (Kroes et al., 2004). As such it can be used to support preliminary hazard 
characterisation and to set priorities in toxicity testing (Barlow, 2005).
The idea that toxicologically insignificant exposure levels to chemicals exist was proposed by Frawley 
due to an increasing demand for toxicity testing (Frawley, 1967). Although his estimation of a 
threshold level was based on limited systemic toxicity studies, the concept became broadly accepted 
(Safford, 2008).
The first toxicological threshold level for chemicals migrating from food packaging, was developed by 
a probabilistic assessment of the distribution of carcinogenic potency data, from rodent lifetime studies 
(Rulis, 1992). Rulis proposed a level of exposure of 0.5 ppb equivalent to an intake of 1.5µg/day/adult
(Safford, 2008) which would be protective for known and unknown carcinogens. The cut-off value 
was then accepted by the US Food and Drug Administration (FDA) as a Threshold of Regulation 
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(ToR), which meant that no further testing was required for substances migrating from packaging into 
food below this level of exposure. This was the first use of TTC concept for regulatory purposes. 
Further development of the TTC concept was carried out by Cheeseman and colleagues, who 
confirmed that the threshold level of 1.5µg/day, proposed by Rulis, is valid for most carcinogens, and 
that the dose would be protective also against other toxic endpoints  (Cheeseman et al., 1999). They 
also proposed higher exposure threshold levels for chemicals lacking structural alerts for 
carcinogenicity, chemicals that were negative in genotoxicity testing and having acute toxicity (LD50) 
values above 1000mg/kg.
The TTC approach was subsequently refined by different authors with the aim of providing a tiered 
approach based mostly on chemical structure and oral systemic toxicity data. Munro and colleagues 
developed a generic threshold for chemicals where non-carcinogenic toxic effects are expected, by 
evaluating the impact of chemical structure on toxicity. For this purpose they applied the Cramer 
decision tree, which places chemicals into three structural classes according to the level of concern 
based on systemic toxicity. The Cramer decision tree approach uses the knowledge on structure 
activity relationships, metabolism, chemical reactivity, human exposure levels and other relevant 
information (Cramer et al., 1978). The decision tree consists of 33 questions. Each question can be 
answered as yes or no, leading to the final classification of a chemical into one of three classes, 
reflecting the presumption of low, moderate and high toxicity. As a result substances are classified into 
one of three classes.
· Class I (Low) contains substances of simple chemical structure with known metabolic 
pathways and innocuous end products which suggest a low order of oral toxicity. 
· Class II (Intermediate) contains substances that are intermediate. They possess structures that 
are less innocuous than those in Class 1 but they do not contain structural features that are 
suggestive of toxicity like those in Class 3. 
· Class III (High) contains substances with a chemical structure that permits no strong initial 
impression of safety and may even suggest a significant toxicity
The Cramer scheme (and its Toxtree implementation, see 5.1) is applicable to organic molecules and 
their salts. Polymers, oligomers and inorganics cannot be classified by the decision tree.
Munro et al. (1996) proposed human exposure thresholds of 1800, 540 and 90•g/person/day for 
classes  II and II, respectively. To further evaluate the thresholds proposed by Munro, an expert group 
was established by International Life Sciences Institute (ILSI) Europe. The group concluded that 
adverse effects on the nervous system, immune system, endocrine system and development were 
covered by the thresholds previously proposed by Munro for the three Cramer classes. An exception 
was identified for organophosphates, which are more toxic. For this group of substances, a specific 
TTC of 18 •g/person/day was derived (Kroes et al., 2004). 
The so-called “cohort of concern” was identified. This includes aflatoxin-like, azoxy- and nitroso-
compounds, which are genotoxic, and TCDD (2,3,7,8-dibenzo-p-dioxin and its analogues) and 
steroids, which are endocrine disruptors. Since these groups of compounds were considered to result in 
the highest risks if present at very low concentrations in the diet, they were excluded from the TTC 
approach. Other exclusions from the TTC approach include polyhalogenated 
dibenzodioxins/dibenzofurans/biphenyls and heavy metals, all of which are known to accumulate in 
the body; and proteins, because of their allergenic potential. For chemicals having structural alerts for 
genotoxicity but which do not belong to the cohort of concern, a TTC of 0.15 •g/day was 
recommended (Kroes et al., 2004).
The ILSI expert group also proposed a decision tree to act as guidance on how and when the TTC 
principle could be applied as a preliminary step in safety evaluation of chemicals (Kroes et al., 2004).
The decision tree is intended for use on chemicals with known structure and low molecular mass. Data 
on total human exposure are relevant for the successful application of the TTC approach. 
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So far, the TTC approach has been successfully applied in the safety assessment of food contaminants 
migrating from packaging by the US FDA, as well as flavouring agents by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA). The European Food Safety Authority (EFSA) uses the TTC 
approach to evaluate flavouring substances, and the European Medicines Agency (EMA) uses it in 
support of marketing applications for genotoxic impurities in pharmaceutical preparations, and 
recommends a TTC of 1.5 •g per day for all but highly potent subset of compounds (EMEA, 2006). 
Although at a draft stage, the US FDA also issued a draft guidance on recommended approaches for 
genotoxic and carcinogenic impurities in drug products enumerating acceptable TTC values, e.g. 1.5 
•g per day for both marketing applications and grater than 1-year clinical trials (FDA, 2008). The 
application of the TTC approach has also been explored for its applicability to consumer products 
(Safford 2008; Felter et al., 2009). It has also been proposed that the TTC could be adapted for 
environmental risk assessment (Barlow, 2005).
The scientific basis of the Cramer TTC scheme and its applicability in different regulatory areas has 
been assessed by various researchers (Phillips et al., 1987) and institutions. For example, an EFSA 
opinion on the applicability of TTC in the food and feed areas is currently being developed and will be 
published in 2011.
5.1 Databases underlying the derivation of TTC values
The main databases that have been used to develop the TTC concept and to derive structure-based 
threshold values (as described in the above-mentioned studies) are summarised in Table 7.
5.2 Software for TTC estimation
One of the best known software tools for supporting TTC estimations is the JRC’s Toxtree software.
Toxtree is a freely available open source software tool that estimates toxic hazard by applying a 
decision tree approach. It was developed by Ideaconsult Ltd (Bulgaria) under the terms of a JRC 
contract. It is designed to be user-friendly and flexible, being capable of extensions and revisions to its 
rulebases (plug-ins). Since it is licensed under the General Public License (GPL), any user has the right 
to modify and redistribute the software in accordance with the GPL licensing conditions. Toxtree can 
be downloaded from the JRC (http://ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?c=TOXTREE) and 
from Sourceforge (https://sourceforge.net/projects/toxtree/)
The current version of Toxtree (v2.1.0, June 2010), includes the following plug-ins (rulebases) related 
to TTC assessment
1) the original Cramer rulebase (Cramer et al., 1978; Figure 1)
The Toxtree implementation of the original Cramer decision has been evaluated by Patlewicz et al. 
(2008).
2) the Cramer rulebase with extensions (Figure 2) 
This rulebase (first available in v1.60, July 2009) works by assigning compounds to Class I, II, or 
III, according to the rules from Cramer, and some extra ones. Several compounds were classified 
by Munro in 1996 as Class I or Class II compounds according to the Cramer rules, even though 
Munro reported low NOEL values upon oral administration (indicating relatively high toxicity). To 
overcome such misclassifications, five rules were introduced to capture the possible toxicity of 
these compounds. This plug-in was developed by Curious-IT, The Netherlands, on behalf of JRC.
3) the TTC decision tree of  Kroes et al. (2004).
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This rulebase (first available in v2.1.0) results in three possible outcomes: a) substance would not 
be expected to be a safety concern; b) negligible risk (low probability of a life-time cancer risk 
greater than 1 in 106); and c) risk assessment requires compound-specific data. It incorporates the 
Benigni/Bossa rules for the identification of genotoxic carcinogens (developed earlier by ISS, 
Rome on behalf of the JRC), and requires the user to input the estimated daily intake.
6. Disclaimer
Any conclusions and opinions expressed in this document are those of the authors as individual 
scientists and do not constitute an official position by the JRC or the European Commission.
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Figure 1. Cramer scheme (original). Yes branch in green. No branch in red. Terminal nodes (labelled 1, 2 
& 3) refer to Cramer classifications I, II and III.
Figure 2. Cramer scheme with extensions decision tree. Yes branch in green. No branch in red. Terminal 
nodes (labelled 1, 2 & 3) refer to Cramer classifications I, II and III.
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Table 1. Literature-based QSAR models for acute toxicity in rodents
Reference Exposure 
route
Endpoint 
predicted
QSAR 
method
Compound class(es) Training 
set size
Test  set 
size
Zhu et al. (2009a) oral LD50 kNN multiple 230 (rat) and 
211 (mouse)
23 (rat) 
and 24 
(mouse)
Zhu et al. (2009b) oral LD50 kNN, RF multiple 3,472 3,913
Fratev (2007) oral GRID allelochemicals 52 21
Garcia-Domenech et al. 
(2007) 
oral RA organophosphorus 39 23
Toporov et al. (2007) oral RA substituted benzenes 
(mostly 
nitrobenzenes)
14 14
Jurani• et al. (2006) oral RA N-alkyl and N-
cycloalkyl 
fluoroacetamides
19 -
Lessigiarska et al. 
(2006) 
oral RA multiple 26 5
Guo et al. (2006) oral CoMFA organophosphorus 30 -
Devillers (2004) oral NIPALS, 
ANN
organophosphorus 51 9
Zahouily (2002) oral RA organophosphorus 47 20
Gough and Hall (1999) oral RA amide herbicides 50 9
oral RA organophosphorus 49 5Eldred and Jurs (1999) 
oral ANN 44 (+5 CVS) 5
Wang and Bai (1998) oral Decision 
tree based 
on twenty-
seven rules
alcohols 95 25
oral RA substituted anilines 103 12Johnson and Jurs (1997) 
oral ANN 87 (+11 
CVS)
11
Zakarya et al. (1996) oral RA amide herbicides 44 -
Jäckel and Klein (1991) oral RA amines and anilines 29 -
Nendza  (1991) oral RA phenylurea herbicides 12 -
Enslein, (1978) oral RA multiple 425 100
Durden (1973) oral RA 2-alkyl- and 2,6-
dialkyl-anilines
8 -
Abbreviations. ANN, artificial neural network; CoMFA, Comparative Molecular Field Analysis; CVS, cross-validation set; ES, expert 
system; kNN, k nearest neighbour; NIPALS, nonlinear estimation by iterative partial least squares; RF, random forest; RA, regression 
analysis.
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Table 2. Software tools for systemic toxicity endpoints 
ENDPOINT
SOFTWARE (AND DEVELOPER)
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 (1
)
ACD/Tox Suite (ToxBoxes) Commercial •
ADMET Predictor (Simulations 
Plus Inc.)
Commercial •
ADME/Tox WEB Freely available •
BioEpisteme Commercial • •
Caesar project models (Mario Negri 
Institute)
Freely available
Derek (Lhasa Ltd) Commercial • • • •
HazardExpert (CompuDrug) Commercial • •
Lazar  (In Silico Toxicology; 
Freiburg university)
Freely available • •
Leadscope (Leadscope) Commercial • • •
MCASE/MC4PC (MultiCASE) Commercial • • • •
MDL QSAR (MDL) Commercial • • •
MolCode Toolbox Commercial •
OASIS-TIMES (Laboratory of 
Mathematical Chemistry, Bourgas 
University)
Commercial
OncoLogic (US EPA) Freely available
Pallas Suite including ToxAlert, 
Cytotoxicity (CompuDrug)
Commercial • •
TerraQSAR (TerraBase) Commercial •
TOPKAT (Accelrys) Commercial • •
Toxtree (JRC) Freely available
Molcode Toolbox ( Molcode Ltd) Commercial •
(1) immunotoxicity other than skin sensitisaton.
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Table 3. Databases containing acute toxicity information
Database Availability Information 
Acutoxbase, linked to the EU FP6 
project ‘A-Cute-Tox’;
https://acubase.amwaw.edu.pl
Access through the 
internet, currently 
restricted to project 
partners
The following data are available for 97 reference 
chemicals (i.e. 52% drugs, 31% industrial 
chemicals, 12% pesticides, 5% others):
in vitro: approx. 100 in vitro assays including 
general acute cytotoxicity, metabolism-mediated 
toxicity, biokinetics, and organ-specific toxicity.
in vivo: Over 2200 LD50 values in rodents (rat 
and mouse) and other animals (e.g. guinea pig, 
dog) with various administration routes (oral, 
intravenous, etc.) compiled from published 
literature.
For 86 reference chemicals, human acute 
poisoning cases from clinical/forensic reports are 
also available.
ChemIDplus, developed by the US 
NLM; 
http://chem.sis.nlm.nih.gov/chemidplus/
Freely available 
through the Internet, 
structure-searchable
Toxicity data for over 139,000 records, retrieved 
from TOXNET® (TOXicology Data NETwork; 
http://toxnet.nlm.nih.gov) which includes HSDB 
(Hazardous Substances Data Bank). The HSDB 
is an older subset of the RTECS database. A 
search for rat and mouse oral LD50 values found 
13,548 and 28,033 records, respectively. 
CEBS, developed by the US NIEHS;
http://cebs.niehs.nih.gov/
Freely available 
through the Internet
In vivo study data and acute dose of a small 
number of known hepatotoxicants to rat.
RTECS, originally compiled and 
maintained (until 2001) by the US 
NIOSH and currently maintained by 
Symyx Technologies. Structure-
searchable through the Symyx Toxicity 
Database:
http://www.symyx.com/products/databas
es/bioactivity/rtecs/index.jsp
Also searchable via the Leadscope 
Toxicity Database
(http://www.leadscope.com/databases/)
Commercial Rat acute oral toxicity (LD50) and acute 
inhalation toxicity (LC50) data compiled from the 
open scientific literature for approx. 7,000 
compounds (organic, inorganic and mixtures), 
including approx. 4000 organic compounds.
TerraBase databases
http://www.terrabase-inc.com/
Commercial Several databases include rat and mouse LD50
values for different product types (natural 
compounds, drugs, pesticides)
ZEBET, compiled by BfR ZEBET;
http://www.dimdi.de
Freely searchable 
through the DIMDI
website. Published in a 
report by ICCVAM
(ICCVAM et al., 2001)
Includes rat or mouse LD50 values (from the 
RTECS database) and cytotoxicity (IC50) data 
for 347 compounds compiled from the open 
literature.
Abbreviations: CEBS, Chemical Effects in Biological Systems; DIMDI, German Institute for Medical Documentation and Information; 
ICCVAM, Interagency Coordinating Committee on the Validation of Alternative Methods; RTECS, Registry of Toxic Effects of 
Chemical Substances; US NLM, US National Library of Medicine; US NIEHS, US National Institute of Environmental Health Sciences; 
US NIOSH, US National Institute of Occupational Safety and Health; BfR ZEBET, Centre for Documentation and Evaluation of 
Alternatives to Animal Experiments of the German Federal Institute for Risk Assessment.
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Table 4. Literature-based QSAR models for chronic toxicity in rodents
Reference Exposure 
route
Endpoint 
predicted
QSAR 
method
Compound 
class(es)
Training 
set size
Test  set size
de Julian-Ortiz et al.  
(2005)
Oral Rat chronic
LOAEL
MLR, LDA multiple 234 17
Garcia-Domenech et al.  
(2006)
Oral Rat chronic 
LOAEL
MLR, LDA multiple 86 16
Mazzatorta et al.  (2008) Oral Rat chronic 
LOAEL
GA and PLS 
for 
descriptors 
selection; 
LOO-SMLR
for model 
generation
multiple 445 none
Matthews et al.  (2004a
and 2004b)
Oral Human 
MRTD and 
NOEL
Classification 
model based 
on SAs
pharmaceuticals 1309 none
Maunz & Helma (2008) Oral Human 
MRTD
SVR pharmaceuticals 1215 None 
(internal 
cross-
validation)
Abbreviations. LDA, linear discriminant analysis; LOO-SMLR, leave-one-out stepwise multiple linear regression; MLR, multiple linear 
regression; SA, structural alerts; SVR, support vector regression.
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Table 5. Databases containing repeated dose toxicity information
Database Availability Information 
US FDA Maximum Recommended Therapeutic Dose 
(MRTD) Database
http://www.fda.gov/AboutFDA/CentersOffices/CDER/u
cm092199.htm
http://www.epa.gov/ncct/dsstox/sdf_fdamdd.html
Freely available MRTD values for 1215 pharmaceuticals from 
clinical trials, mostly by oral administration 
and daily treatments, usually for 3-12 months. 
(with 5% of the pharmaceuticals being 
administered intravenously and/or 
intramuscularly). Includes structures. 
Available from FDA and EPA DSSTOX
RepDose database developed by Fraunhofer Institute of 
Toxicology and Experimental Medicine
http://www.fraunhofer-repdose.de/
Freely available 
for online 
searching 
Subacute to chronic, oral and inhalation 
NOELs and LOAELs and for 655 industrial 
chemicals (version 2009); publicly available 
rat, mouse and dog studies; includes 
structures, physicochemical properties and 
study designs
Mazzatorta et al. (2008)
http://pubs.acs.org/doi/suppl/10.1021/ci8001974
Freely available 
as MS Excel file
molecular structures (encoded as canonical 
SMILES strings) with LOAEL values for 445 
unique chemicals
The Munro and Cramer datasets:
http://apps.ideaconsult.net:8080/ambit2/dataset/26538?
max=100
http://apps.ideaconsult.net:8080/ambit2/dataset?search=
Cramer
http://www.efsa.europa.eu/en/scdocs.htm
Available from 
AMBIT website. 
Also expected to
be available from 
EFSA in 2011
Munro database contains 612 structurally 
well-defined organic chemicals and 
aassociated NOELs
Cramer dataset contains 83 structures (no 
toxicological data)
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Table 6. Literature-based (Q)SAR models for organ- and system-specific toxicity
Reference Endpoint Compound class(es) Dataset Size (1)
Gu et al. (2009) Neurotoxicity, immunotoxicity (i.e., AHH and 
EROD induction potency)
PADDs 13
Gu et al. (2009) Neurotoxicity, immunotoxicity (i.e., AhR binding 
affinity)
PADDs 25
Tichý et al. (2009) rat hepatocyte toxicity Aliphatic alcohols, 
ketones, esters
15
Matthews et al. 
(2009b)
Human clinical hepatobiliary and renal tract 
toxicities
pharmaceuticals ~1600
Roy et al. (2008) rat hepatocyte toxicity phenols 31
Chan et al. (2008a) human and rat hepatocyte toxicity p-benzoquinones 10
Chan et al. (2008b) rat hepatocyte toxicity acrylates and 
methacrylates
10
Chan et al. (2008c) rat hepatocyte toxicity •,•-unsaturated 
aldehydes
11
Chan et al. (2007) human and rat hepatocyte toxicity halobenzenes 12
Pessah et al. (2005) developmental neurotoxicity (ryanodine receptor 
type 1-binding affinity) - SAR
Ortho-substituted PCBs 28
Jenkins et al. (2004) developmental neurotoxicity (neurite outgrowth 
and cell death) - SAR
Organotin 4
Moridani et al. 
(2003)
rat hepatocyte toxicity phenols 31
Jolivette et al. 
(2002)
Rat in vivo nephrotoxicity 1,2- and 1,4-
naphthoquinones
9
Yazal et al. (2001) in vitro neurotoxicity (AChE  inhibition, IC50) organophosphorous 8
Crofton (1996) rat in vivo neurotoxicity (hyperactivity) - SAR triazoles 16
Nevalainen et al. 
(1994)
Neurotoxicity, immunotoxicity (aryl hydrocarbon 
receptor binding affinity)
PCDDs 14
Nevalainen et al. 
(1994)
Neurotoxicity, immunotoxicity (aryl hydrocarbon 
receptor binding affinity)
PCDFs 35
Nevalainen et al. 
(1994)
Neurotoxicity, immunotoxicity (aryl hydrocarbon 
receptor binding affinity)
PCBs 14
Nevalainen et al. 
(1994)
Neurotoxicity, immunotoxicity (aryl hydrocarbon 
receptor binding affinity)
PCDEs 12
Mager (1982) rat in vivo neurotoxicity (ataxia) organophosphorous 22
(1) Training set + test set (when applicable)
Abbreviations. Aryl hydrocarbon hydroxylase (AHH); Aryl hydrocarbon receptor (AhR); 7-ethoxyresorufin O-deethylase (EROD); 
Polyhalogenateddibenzo-p-dioxins (PADDs); polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), polychlorinated 
biphenyls (PCBs), and diphenylethers (PCDEs).3.6 Genotoxicity (including mutagenicity) and carcinogenicity.
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Table 7. Summary of Threshold of Toxicological Concern datasets 
Author Database (number of 
substances)
Evaluated experimental data  (count 
of data)
Conclusions
Rulis (1986) CPDB carcinogens (343) Chronic long term exposure Proposed ToR of 0.5 ppb equivalent to 
1.5µg/day adult intake
Munro (1996) JECFA, US EPA IRIS, non tumour 
from NTP, DART, literature (611)
Oral toxicity data from chronic, sub-chronic, 
reproductive, teratology studies
Proposed TTC for the three Cramer classes: 
1880 µg/day for Class I; 540 µg/day for Class
II; 90 µg/day for Class III
CPDB carcinogens (709) Short-term toxicity data, genotoxicity testing Confirmation of the validity of 1.5µg/day for 
subsets of potent and non potent carcinogens 
Cheeseman (1999)
RTECS (3306)
RTECS (2542)
Oral reproductive toxicity data
Data from other repeat-dose toxicity tests
Confirmation of the validity of 1.5µg/day for 
other toxic effects
Munro DB 
JECFA, US EPA IRIS, non tumour 
from NTP, DART, literature (611)
Subchronic neurotoxicity data (45)
Acute neurotoxicitytoxicity data (37)
Developmental neurotoxicity (52)
Immunotoxicity (37)
Developmental (81)
Confirmation of TTC proposed for the three 
Cramer classes, also for other toxic endpoints 
Lower TTC of 18 µg/day for 
organophosphates 
ILSI working group (2000, 2004)
Cheesman's CPDB carcinogens 
(709) extended (730)
Identified 5 groups of chemicals of highest 
concern “cohort of concern”: 3 groups of 
genotoxic compounds (aflatoxin-like 
compounds, azoxy-compounds, nitroso-
compounds) and 2 groups of endocrine 
disruptors (TCDD, steroids)
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